Information deficits in the summary of product characteristics preclude an optimal management of drug interactions: a comparison with evidence from the literature
暂无分享,去创建一个
Walter E. Haefeli | Hermann Brenner | Meret Martin-Facklam | H. Brenner | W. Haefeli | V. Bergk | C. Gasse | M. Martin-Facklam | Verena Bergk | Christiane Gasse
[1] W. Haefeli,et al. Dose individualisation in patients with renal insufficiency: does drug labelling support optimal management? , 2004, European Journal of Clinical Pharmacology.
[2] Drug labeling should be kept current , 2003, Clinical pharmacology and therapeutics.
[3] F. Haaijer-Ruskamp,et al. The development of polypharmacy. A longitudinal study. , 2000, Family practice.
[4] T. Walley,et al. Influences on GPs' decision to prescribe new drugs-the importance of who says what. , 2003, Family practice.
[5] Aileen B. Sedman,et al. A longitudinal study , 1987 .
[6] I. Anderson,et al. Incorrect overdose management advice in the Physicians' Desk Reference. , 1997, Annals of emergency medicine.
[7] Jenny Field,et al. General practitioners' perceptions of the route to evidence based medicine: a questionnaire survey , 1998, BMJ.
[8] J K Aronson. Drug interactions-information, education, and the British National Formulary. , 2004, British journal of clinical pharmacology.
[9] M. Bonati,et al. Prescribing information in 26 countries: a comparative study , 2003, European Journal of Clinical Pharmacology.
[10] R. Kapp. Stockley’s Drug Interactions, 6th Edition , 2004 .
[11] Jennifer C. Lin,et al. The Effect of Converting from Pravastatin to Simvastatin on the Pharmacodynamics of Warfarin , 1999, Journal of clinical pharmacology.
[12] J. Hallas,et al. Polypharmacy and the risk of drug-drug interactions among Danish elderly. A prescription database study. , 1998, Danish medical bulletin.
[13] H. Brenner,et al. Drug interactions in primary care: Impact of a new algorithm on risk determination , 2004, Clinical pharmacology and therapeutics.
[14] H. Pan. Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase , 2005, European Journal of Clinical Pharmacology.
[15] J S Cohen,et al. Dose discrepancies between the Physicians' Desk Reference and the medical literature, and their possible role in the high incidence of dose-related adverse drug events. , 2001, Archives of internal medicine.
[16] W. Haefeli,et al. Requirements for a successful implementation of drug interaction information systems in general practice: results of a questionnaire survey in Germany , 2004, European Journal of Clinical Pharmacology.
[17] Raymond L. Woosley,et al. Assessment and reporting of clinical pharmacology information in drug labeling , 2000, Clinical pharmacology and therapeutics.